Trial Profile

The Immunogenicity and Safety of Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 137173A (Primary)
Indications Herpes zoster
Focus Pharmacodynamics

Most Recent Events

04 Jul 2024 According to ClinicalTrials.gov: US National Institutes of Health record the trial was terminated as they were unable to recruit adequate numbers of participants to answer the research question.
04 Jul 2024 Status changed from recruiting to discontinued.
30 Aug 2023 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com